Statins halt polycystic liver disease by reprogramming metabolism and normalizing mitochondrial bioenergetics in cystic cholangiocytes
Mitochondrial and metabolic dysregulation are central to the pathogenesis of PLD. Targeting cholesterol metabolism with statins represents a promising therapeutic strategy to slow disease progression and reduce cyst burden.
Authors
- Ainhoa Dubrana Lapitz
- Beatriz Vicente Val
- L. Bujanda
- María J. Perugorria (ORCID: https://orcid.org/0000-0002-7636-0972)
- Mikel Ruiz de Gauna (ORCID: https://orcid.org/0000-0002-6619-5512)
- Enara Markaide
- Pedro M. Rodrigues (ORCID: https://orcid.org/0000-0002-3256-5060)
- Jesús M. Bañales (ORCID: https://orcid.org/0000-0002-5224-2373)
- Thomas Bais (ORCID: https://orcid.org/0009-0008-3649-6948)
- Josu Urretabizkaia-Garmendia
- Joost P H Drenth
- R. E. Castro
- Irene Olaizola
- Patricia Aspichueta
- Xabier Buqué
- Irune Lasa-Elosegui
- Ron Gansevoort
Institutions
- Ikerbasque (ES)
- University Medical Center Groningen (NL)
- University of Lisbon (PT)
- University of the Basque Country (ES)
- University of Groningen (NL)
- Instituto de Salud Carlos III (ES)
- BioCruces Health research Institute (ES)
- Biogipuzkoa Health Research Institute (ES)
- Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (ES)
- ERN GUARD-Heart (NL)
- Universidad de Navarra (ES)
Publication Details
- Journal
- Hepatology
- Published
- 2026-02-10
- DOI
- https://doi.org/10.1097/hep.0000000000001711
- Primary Topic
- Genetic and Kidney Cyst Diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.00